For US Healthcare Professionals Only
Prescribing information
Open menuMenu

ELITEK® (rasburicase) was studied in adults at high and intermediate (potential) risk of TLS1

92%

of adult patients were at high risk for tumor lysis syndrome (TLS) at baseline1
 

82%

of adult patients had normal uric acid levels (≤7.5 mg/dL) at baseline1
 

Adult patients meeting at least 1 of the following criteria were enrolled in the pivotal trial1:

HIGH RISK1-3

Aggressive lymphoma/leukemia (defined by REAL)

  • DLBCL
  • Anaplastic large cell lymphoma
  • Peripheral T-cell lymphomas
  • Burkitt lymphoma
  • Lymphoblastic lymphoma
  • CLL

AML

Elevated plasma uric acid levels (>7.5 mg/dL) at baseline

High-grade MDS with >10% bone marrow blast involvement

CML in blast crisis

INTERMEDIATE (POTENTIAL) RISK1

Aggressive lymphoma/leukemia, not limited to the REAL definition, with LDH ≥2x the upper limit of normal

Any stage III to IV aggressive lymphoma or leukemia

Stage I or II aggressive disease with bulky lymph node/tumor (>5 cm) involvement

See full Prescribing Information.

Michael R.Bishop, MD

EXPERT REVIEW VIDEO

Watch Dr. Michael R. Bishop explain why patients with uric acid levels of ≥7.5 mg/dL would be considered at high risk for developing TLS

WATCH NOW
ELITEK Efficacy and Safety Flashcard

Use this efficacy and safety flashcard to see the head-to-head pivotal trial data between ELITEK and allopurinol

DOWNLOAD NOW

EXPLORE ADULT EFFICACY

Antihyperuricemic therapy in all 3 arms was initiated prior to anticancer therapy1,4

  • Phase 3: randomized, multicenter, open-label study in adult patients (N=275) with leukemia, lymphoma, and solid tumor malignancies at risk for hyperuricemia and TLS
  • Primary endpoint: response rate defined as the proportion of adult patients with plasma uric acid levels maintained at ≤7.5 mg/dL between 3 and 7 days after initiation of antihyperuricemic treatment
ADULT PIVOTAL TRIAL DESIGN1,4
The adult pivotal trial design (N=275) randomized patients 1:1:1 by treatment type. 92 patients received ELITEK alone (0.2 mg/kg/day), administered on days 1, 2, 3, 4, and 5; 92 patients received ELITEK (0.2 mg/kg/day) on days 1, 2, and 3, and allopurinol (300 mg/day) on days 3, 4, and 5; 91 patients received allopurinol alone (300 mg/day) on days 1, 2, 3, 4, and 5. Anticancer therapy was initiated 4 to 24 hours after the first antihyperuricemic dose. 
ADULT PIVOTAL TRIAL DESIGN1,4
The adult pivotal trial design (N=275) randomized patients 1:1:1 by treatment type. 92 patients received ELITEK alone (0.2 mg/kg/day), administered on days 1, 2, 3, 4, and 5; 92 patients received ELITEK (0.2 mg/kg/day) on days 1, 2, and 3, and allopurinol (300 mg/day) on days 3, 4, and 5; 91 patients received allopurinol alone (300 mg/day) on days 1, 2, 3, 4, and 5. Anticancer therapy was initiated 4 to 24 hours after the first antihyperuricemic dose. 
See how these adults responded to treatment with ELITEK

EXPLORE ADULT EFFICACY

AML=acute myeloid leukemia; CLL=chronic lymphocytic leukemia; CML=chronic myeloid leukemia; DLBCL=diffuse large B-cell lymphoma; LDH=lactate dehydrogenase; MDS=myelodysplastic syndrome; REAL=Revised European American Classification of Lymphoid Neoplasms.

References: 1. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-4213. 2. Jakić-Razumović J, Aurer I. The World Health Organization classification of lymphomas. Croat Med J. 2002;43(5):527-534. 3. Nicolaides C, Dimou S, Pavlidis N. Prognostic factors in aggressive non-Hodgkin’s lymphomas. Oncologist. 1998;3(3):189-197. 4. ELITEK [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC.

INDICATION

ELITEK is indicated for the initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. ELITEK is indicated only for a single course of treatment.

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS

  • Hypersensitivity Reactions: ELITEK can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue ELITEK in patients who experience a serious hypersensitivity reaction.
  • Hemolysis: Do not administer ELITEK to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue ELITEK in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting ELITEK.
  • Methemoglobinemia: ELITEK can result in methemoglobinemia in some patients. Immediately and permanently discontinue ELITEK in patients developing methemoglobinemia.
  • Interference with Uric Acid Measurements: ELITEK enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in prechilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection.

CONTRAINDICATIONS

ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.

USE IN SPECIFIC POPULATIONS
  • Pregnancy: Consider the benefits and risks of ELITEK and possible risks to the fetus when prescribing ELITEK to a pregnant woman
  • Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with ELITEK and for 2 weeks after the last dose

Please see full Prescribing Information, including Boxed WARNING.

MAT-US-2020411-v2.0-08/2022
Last Updated: August 2022-08-01YYYY